DnB NXT October 19th, 2016 Oslo Innovation Week
Regenics AS presents at DnB NXT October 19th 2016
Succesfull placement of share issue August 2016
Regenics announces the succesfull private placement of new shares.
DnB Healtcare conference 2016
Regenics presented at DnB Healtcare conference 2016
Regenics publish data on vehicle for Vernex® at Drug Delivery meeting, France
Regenics publish data on its carrier/vehicle GMO to be used in the CE marking device for wound healing, 4th Congress of Drug Delivery, France. September 25-28, 2016
Regenics in press - Presentation in GENIALT from the Norwegian Biotechnology council
Press: The Norwegian Biotechnology Advisory Board monthly publication, GENIALT, August 2016, focus on Regenics roe technology. 
Data Protection Officer
Regenics appoints Chief Medical Officer as Data Protection Officer (Personvern ombud).
Vernex™ Medical device non-binding opinion by SLV
The Norwegian Medicines Agency (SLV) has on August 10th 2016 preliminary reviewed the regulatory status of Vernex™. 
TGA Sciences, Inc., US provides collagen data for salmon roe extract
Regenics releases salmon roe collagen boosting data in human fibroblasts performed by TGA Sciences, Inc., US.  
Regenics AS Annual Report 2015
Regenics post a first positive 2015 result with topline in excess of 4 mill NOK. 
Protocol from Extraordinary Annual Meeting July 11th 2016
July 11th 2016 Protocol from Extraordinary Annual Meeting July 11th 2016
Canadian National Patent 2016
Canadian National Patent issued to Regenics' technology on June 28, 2016.
Notice of Extraordinary Annual Meeting July 11th 2016
June 27th 2016 Notice of Annual Meeting July 11th 2016. The Annual Meeting 2016 will tale place at the Companys site Nycovn. 2, Oslo from 3 pm to 5 pm.
Protocol from Annual Meeting June 22nd 2016
June 22nd 2016 Protocol from Annual Meeting June 22nd 2016
Regenics AS Annual Report 2016
Regenics post a positive 2016 result with topline of 0.35 mill NOK. 
Graduate students summer 2016
Regenics welcomes 2 summer students for intership
Vernex™ clinical study approved by REK
REK the Regional Ethics Commitee of Norway has approved REG 002 a clincial safety study in humans. 

<<  <   Page 2 of 4   >  >>

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.